NASDAQ:PHIO Phio Pharmaceuticals Q3 2025 Earnings Results & Report $0.98 +0.01 (+0.59%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$0.96 -0.01 (-1.51%) As of 10/9/2026 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Phio Pharmaceuticals beat analyst earnings expectations in its Q3 2025 results, released November 13, 2025. The company reported EPS of -$0.44 versus the -$0.45 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 13, 2025TimeBefore Market Opens Phio Pharmaceuticals EPS ResultsActual EPS-$0.44Consensus EPS -$0.45Beat/MissBeat by +$0.01One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersPhio Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsPhio Pharmaceuticals' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile Phio Pharmaceuticals Q3 2025 Earnings FAQ Did Phio Pharmaceuticals beat earnings estimates for Q3 2025? Phio Pharmaceuticals (NASDAQ:PHIO) reported earnings of -$0.44 per share for Q3 2025, beating the consensus estimate of -$0.45. The report was announced on Thursday, November 13, 2025. When is Phio Pharmaceuticals' next earnings date? Phio Pharmaceuticals' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Phio Pharmaceuticals on the company's earnings history page. Phio Pharmaceuticals Earnings HeadlinesPhio Pharmaceuticals Highlights 85% Response Rate as PH-762 Nears Phase 2bOctober 10 at 4:03 AM | americanbankingnews.comPhio Announces Key PH-762 Milestone with FDA Submission for Next Stage of Cutaneous Squamous Cell CarcinomaSeptember 14, 2026 | markets.businessinsider.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 11 at 1:00 AM | Stansberry Research (Ad)Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell CarcinomaSeptember 14, 2026 | insidermonkey.comPhio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell CarcinomaSeptember 14, 2026 | finance.yahoo.comPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894August 12, 2026 | finanznachrichten.deSee More Phio Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Phio Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Phio Pharmaceuticals and other key companies, straight to your email. Email Address About Phio PharmaceuticalsPhio Pharmaceuticals (NASDAQ:PHIO) is a clinical-stage biotechnology company focused on developing immuno-oncology treatments based on its INTASYL self-delivering RNAi technology. The platform is designed to enable small interfering RNA (siRNA) molecules to enter cells without the use of conventional delivery vehicles and to reduce the expression of selected genes involved in cancer biology and immune-system activity. The company’s pipeline has included product candidates intended to improve the ability of immune cells to recognize and destroy tumors. Its programs have included PH-762, an investigational therapy designed to inhibit PD-1 expression in immune cells, and other INTASYL-based candidates targeting pathways such as TIGIT and the immunosuppressive tumor microenvironment. Phio has evaluated its technology in preclinical research and early-stage clinical development, including potential use as a treatment administered directly into tumors or in combination with other immunotherapies. Phio Pharmaceuticals was previously known as RXi Pharmaceuticals and adopted its current name in 2017. The company is based in Marlborough, Massachusetts, and has focused primarily on oncology research and development. As a development-stage biotechnology business, its activities have centered on advancing its proprietary platform and product candidates rather than selling approved commercial medicines.View Phio Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
